Roche

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Roche and other ETFs, options, and stocks.

About RHHBY

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. 

CEO
Thomas Schinecker
CEOThomas Schinecker
Employees
112,774
Employees112,774
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1896
Founded1896
Employees
112,774
Employees112,774

RHHBY Key Statistics

Market cap
396.09B
Market cap396.09B
Price-Earnings ratio
24.38
Price-Earnings ratio24.38
Dividend yield
1.68%
Dividend yield1.68%
Average volume
1.47M
Average volume1.47M
High today
$61.49
High today$61.49
Low today
$59.00
Low today$59.00
Open price
$59.48
Open price$59.48
Volume
539.22K
Volume539.22K
52 Week high
$61.49
52 Week high$61.49
52 Week low
$40.07
52 Week low$40.07

RHHBY News

TipRanks 17h
Roche says Sefaxersen trial shows meaningful reduction in proteinuria

Ionis Pharmaceuticals (IONS) partner Roche (RHHBY) announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with prim...

Investing.com 22h
Zymeworks stock surges on $813M Roche licensing deal - Investing.com

...

Zymeworks stock surges on $813M Roche licensing deal - Investing.com
TipRanks 1d
Zymeworks signs collaboration and license agreement with Roche for ZW209

Zymeworks (ZYME) announced that it has entered into a global license and collaboration agreement with Roche (RHHBY) for the research, development and commercial...

Analyst ratings

54%

of 24 ratings
Buy
54.2%
Hold
41.7%
Sell
4.2%

More RHHBY News

TipRanks 1d
Roche upgraded to Buy from Hold at Deutsche Bank

Deutsche Bank upgraded Roche (RHHBY) to Buy from Hold with a price target of CHF 500, up from CHF 340, post the Q3 report. The firm says physician feedback on g...

Investor's Business Daily 2d
Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma Sales

Technology Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma Sales Licensing Roche (RHHBY) stock wasn't active yet early Thursday after the S...

Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma Sales
TipRanks 2d
Roche reports 9M group sales CHF 46.5B vs. CHF 45.9B last year

In the first nine months of 2026, Roche (RHHBY) sales were +6% at CER, +1% when reported in CHF, to CHF 46.5B due to strong demand for pharmaceutical products a...

TipRanks 4d
Roche upgraded to Outperform from Underperform at Oddo BHF

Oddo BHF analyst Florent Cespedes double upgraded Roche (RHHBY) to Outperform from Underperform with a price target of CHF 440, up from CHF 300. The firm cites...

TipRanks 5d
Hansoh Pharmaceutical enters collaboration, license agreement with Roche

Hansoh Pharmaceutical Group (HNSPF) announces that it has entered into a strategic collaboration and license agreement with Roche (RHHBY). This agreement marks...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.